The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
A comparison between ranibizumab and bevacizumab of the incidence of systemic serious adverse events (SAEs) among patients with neovascular age-related macular degeneration (nAMD) who participated in a large-scale randomized trial. Use of individual patient data, rather than aggregate data, allowed adjustment for strong predictors of SAEs.Relative safety of ranibizumab and bevacizumab is important...
To compare baseline characteristics, visual acuity (VA), and morphologic outcomes between eyes with hard exudate (HE) at baseline and all other eyes among patients with neovascular age-related macular degeneration (NVAMD) treated with anti–vascular endothelial growth factors (VEGFs).Prospective cohort study within the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).Patients...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.